Dealmaking Quarterly Statistics, Q4 2020
A Look At M&A And Alliance Activity Across Medical Device And In Vitro Diagnostics Industries, October-December 2020
During Q4, medical device company M&A values reached $5.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $3.3bn.
You may also be interested in...
BTIG analyst expects SeaSpine’s acquisition of 7D Systems will help SeaSpine morph into a procedurally integrated solutions provider.
GenMark’s syndromic panel testing portfolio complements Roche’s molecular diagnostics business.
With the addition of Decipher, Veracyte now offers tests for seven of the 10 most common types of cancer in the US.